The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://jayapzcm363320.wikimidpoint.com/6467970/glp_3_retatrutide_a_comparative_analysis